CD9 and prostate carcinoma: An increase in Tspan29 and Prostate Specific Membrane Antigen (PSMA) double-positive plasma-derived circulating vesicles has been reported in patients with advanced metastatic prostate cancer, whereas double-positive Tspan29 and Tspan30 extracellular vesicles (EVs) are significantly increased in patients with limited prostate cancer [86].